18501909. METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA simplified abstract (Genentech, Inc.)
Contents
- 1 METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA
Organization Name
Inventor(s)
Ahmed Hamed Salem of Libertyville IL (US)
Jalaja Potluri of North Chicago IL (US)
Jiuhong Zha of Chicago IL (US)
Mehrdad Mobasher of San Francisco CA (US)
Wan-Jen Hong of Mountain View CA (US)
METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA - A simplified explanation of the abstract
This abstract first appeared for US patent application 18501909 titled 'METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA
Simplified Explanation
Methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine are disclosed in this patent application. Additionally, methods of managing cytopenia in such a patient are also provided.
- The patent application focuses on treating AML in patients with cytopenia who are undergoing a combination therapy of venetoclax and azacitidine.
- The methods described in the patent application aim to effectively manage cytopenia in these patients, which is a common side effect of the combination therapy.
- The innovation addresses the need for improved treatment strategies for AML patients with cytopenia, potentially enhancing their overall outcomes and quality of life.
Potential Applications
The technology described in this patent application could be applied in the following areas:
- Oncology
- Hematology
- Pharmaceutical industry
Problems Solved
The technology presented in this patent application helps address the following issues:
- Managing cytopenia in AML patients undergoing specific combination therapy
- Improving treatment outcomes for AML patients with cytopenia
- Enhancing the overall quality of life for AML patients
Benefits
The technology offers the following benefits:
- Improved management of cytopenia in AML patients
- Enhanced treatment efficacy for AML patients on combination therapy
- Potential for better patient outcomes and quality of life
Potential Commercial Applications
The technology outlined in this patent application could have commercial applications in:
- Pharmaceutical companies developing AML treatments
- Healthcare providers specializing in oncology and hematology
Possible Prior Art
One potential prior art in this field could be studies or patents related to managing cytopenia in cancer patients undergoing combination therapies. Research on the efficacy of venetoclax and azacitidine in AML treatment may also be relevant.
Unanswered Questions
How does this technology compare to existing treatments for AML patients with cytopenia?
The patent application does not provide a direct comparison with other existing treatments for AML patients with cytopenia. Further research or clinical trials may be needed to evaluate the efficacy and safety of this method compared to current standards of care.
Are there any potential long-term side effects or risks associated with the methods described in the patent application?
The patent application does not delve into potential long-term side effects or risks associated with the described methods. Additional studies or post-market surveillance may be necessary to assess the long-term safety profile of this treatment approach.
Original Abstract Submitted
Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.
